Kirby McInerney LLP is investigating potential claims against the Board of Directors of Chelsea Therapeutics International, Ltd. (“Chelsea Therapeutics” or the “Company”) (NASDAQ: CHTP) concerning the proposed acquisition of the Company by H. Lundbeck A/S (“Lundbeck”). Under the terms of the definitive merger agreement, Chelsea Therapeutics stockholders will receive $6.44 in cash and up to $1.50 in Contingent Value Rights for each share of Chelsea Therapeutics owned, representing a total potential consideration of up to $658 million.

The investigation concerns whether the Chelsea Therapeutics Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the proposed consideration adequately values Chelsea Therapeutics’ common stock.

If you are a Chelsea Therapeutics stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to

Copyright Business Wire 2010